Literature DB >> 31678293

High-dose omalizumab use in patients with chronic spontaneous urticaria.

Mehran Alizadeh Aghdam1, Fenne van den Broek2, Feiko Rijken2, Andre Cornelis Knulst2, Heike Röckmann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31678293     DOI： 10.1016/j.jaip.2019.10.018

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  6 in total

1.  Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients.

Authors:  Coco Dekkers; Mehran Alizadeh Aghdam; Marlies de Graaf; André C Knulst; Yolanda Meijer; Juul M P A van den Reek; Marike B Stadermann; Heike Röckmann
Journal:  Pediatr Allergy Immunol       Date:  2021-01-18       Impact factor: 6.377

2.  Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis - A Real-life Experience.

Authors:  Mohamed Abuzakouk; Omar K H A Ghorab; Ali S Wahla; Zaid Zoumot; Mohsen Nasir; Deepa Grandon; Mateen H Uzbeck; Fulvio Salvo; Irfan Shafiq
Journal:  Open Respir Med J       Date:  2020-12-31

Review 3.  Pediatric usage of Omalizumab: A promising one.

Authors:  Lin Yu; Huishan Zhang; Jianwei Pan; Leping Ye
Journal:  World Allergy Organ J       Date:  2021-12-11       Impact factor: 4.084

4.  Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria.

Authors:  Maria Maddalena Sirufo; Enrica Maria Bassino; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

5.  Omalizumab treatment for chronic spontaneous urticaria: data from Turkey.

Authors:  Rabia Oztas Kara; Bahar Sevimli Dikicier; Mahizer Yaldiz; Busra Koku; Nur Cihan Çosansu; Berna Solak
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664

Review 6.  Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.

Authors:  Martin Metz; Zahava Vadasz; Emek Kocatürk; Ana M Giménez-Arnau
Journal:  Clin Rev Allergy Immunol       Date:  2020-08       Impact factor: 8.667
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.